AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26882041
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering therapy in patients with preserved LVEF (>55%)
Trial: 26882041
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering therapy in patients with intermediate LVEF (45-55%)
Trial: 26882041
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering therapy in patients with reduced LVEF (<45%)
Trial: 25424952
Drug: Co-administered qHPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administered qHPV and HAV/HBV vaccine
Trial: 25424952
Drug: Separated doses
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separated doses of qHPV and HAV/HBV vaccine
Trial: 25424952
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups post-second dose of qHPV and HAV/HBV
Trial: 20080850
Drug: T(3) therapy
RxNorm normalized name: levothyroxine sodium 0.3 MG [Levo-T]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T(3) therapy (0.8 microg . kg(‐1) bolus; infusion 0.113 microg . kg(‐1) . h(‐1))
Trial: 20080850
Drug: T(3) therapy
RxNorm normalized name: levothyroxine sodium 0.3 MG [Levo-T]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T(3) therapy
Trial: 15290000
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg QD
Trial: 15290000
Drug: Desipramine 50
RxNorm normalized name: desipramine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 50 mg BID
Trial: 11710819
Drug: Granisetron 3
RxNorm normalized name: granisetron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3 mg plus dexamethasone 10 mg
Trial: 11710819
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg plus dexamethasone 10 mg
Trial: 9164214
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial chemotherapy (HAI)
Trial: 7967418
Drug: NHL-BFM 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHL-BFM 90 therapy
Trial: 31959224
Drug: Tailored cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored cognitive behavioural therapy (CBT) intervention
Trial: 31231865
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin (ATV) daily for a median of 27 days
Trial: 23122836
Drug: 20% Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Intralipid (IL) infusion
Trial: 11711768
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299V (LP299V) in liquid suspension
Trial: 9204357
Drug: iopentol (Imagopaque
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopentol (Imagopaque 300 mg I/ml)
Trial: 9204357
Drug: amidotrizoate (Peritrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amidotrizoate (Peritrast 300 mg I/ml)
Trial: 7953013
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral haloperidol
Trial: 7953013
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of oral haloperidol
Trial: 7953013
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of oral haloperidol
Trial: 7953013
Drug: Adjunctive lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive lorazepam (for non-responders)
Trial: 3673203
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of 3 micrograms given at 0, 1 and 6 months
Trial: 3673203
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of 3 micrograms given at 0, 1 and 2 months
Trial: 23664712
Drug: Antidepressant pharmacotherapy
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant pharmacotherapy (three different regimens) for 12 weeks
Trial: 21615671
Drug: muraglitazar (MURA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muraglitazar (MURA), 5 mg/day
Trial: 19560327
Drug: D-camphor-crataegus berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-camphor-crataegus berry extract combination (Korodin)
Trial: 16469981
Drug: High-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.4 mg aglycone isoflavones/d)
Trial: 16469981
Drug: Low-isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg aglycone isoflavones/d)
Trial: 11693319
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy with standardized 3-month omeprazole treatment
Trial: 11693319
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standardized 3-month omeprazole treatment
Trial: 3108171
Drug: Ritanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (20 mg daily)
Trial: 3108171
Drug: Lorazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (5 mg daily)
Trial: 26144968
Drug: Citalopram (serotonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (serotonin reuptake inhibitor)
Trial: 28116581
Drug: Atomoxetine (noradrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (noradrenaline reuptake inhibitor)
Trial: 25945865
Drug: Carvedilol treatment
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol treatment (group A, n = 16)
Trial: 25945865
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (group B, n = 20)
Trial: 23637276
Drug: Topical shellac
RxNorm normalized name: Shellac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical shellac
Trial: 23637276
Drug: 10% povidone-iodine
RxNorm normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% povidone-iodine (PVP-I) solution
Trial: 21525157
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal testosterone replacement therapy
Trial: 21525157
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Risedronate + Testosterone)
Trial: 18972301
Drug: Pressurized metered-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized metered-dose inhaler
Trial: 16432268
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablet (ODT) administered sublingually
Trial: 16432268
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablet (ODT) administered normally
Trial: 16432268
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral tablet (SOT)
Trial: 8601566
Drug: MAB +
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAB + MTX (methotrexate, 50 mg/m2/week)
Trial: 8601566
Drug: MAB (orchiectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAB (orchiectomy followed by flutamide therapy)
Trial: 6430328
Drug: Inhaled lactose-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lactose-free sodium cromoglycate powder (C)
Trial: 31300595
Drug: Dexmedetomidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (100 µg)
Trial: 24046070
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IDH1 with CEA, CA125, and Cyfra21‐1
Trial: 19584895
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (6 g ALA from 30 g flaxseed oil)
Trial: 19584895
Drug: Ground flaxseed
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground flaxseed (6 g ALA from 30 g ground flaxseed)
Trial: 15029102
Drug: Repaglinide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (1 mg x 2/die)
Trial: 15029102
Drug: Glimepiride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2 mg/die)
Trial: 1770553
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg/d)
Trial: 29168028
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of steroids (prednisolone intravenously followed by methylprednisolone orally)
Trial: 29168028
Drug: Intratympanic administration
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic administration of methylprednisolone
Trial: 29168028
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of systemic and intratympanic steroids
Trial: 24485548
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of MMRV
Trial: 24485548
Drug: MMR at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group)
Trial: 24485548
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of MMR (control group)
Trial: 18600386
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Trial: 18600386
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy (amoxicillin, clarithromycin, proton pump inhibitor)
Trial: 18600386
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (omeprazole, bismuth subcitrate, doxycycline, metronidazole)
Trial: 18600386
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after quadruple therapy
Trial: 16077384
Drug: Ginsenosides compound
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenosides compound (1.35 mg/kg intravenously before and throughout cardiopulmonary bypass)
Trial: 11836266
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg/d plus KCl placebo)
Trial: 11836266
Drug: Hydrochlorothiazide (HCTZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ; 25 mg plus 20 mmol KCl/d)
Trial: 2901566
Drug: Ditiocarb sodium
RxNorm normalized name: Ditiocarb zinc
DrugBank: Ditiocarb (DB02520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ditiocarb sodium ('Imuthiol') 10 mg/kg body weight given orally once a week
Trial: 31738283
Drug: Dextrose prolotherapy
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose prolotherapy (5 ml of 30% dextrose, 4 ml of saline, and 1 ml of 2% lidocaine mixture)
Trial: 31738283
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (9 ml of saline and 1 ml of 2% lidocaine mixture)
Trial: 26946985
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg/d
Trial: 26946985
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (erlotinib alone 150 mg/d)
Trial: 22538152
Drug: 5 mm
RxNorm normalized name: SUR-FIT 45 mm Wafer, Small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mm needle with 20 U insulin diluent
Trial: 22538152
Drug: 8 mm
RxNorm normalized name: potassium 8 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mm needle with 20 U insulin diluent
Trial: 22538152
Drug: 5 mm
RxNorm normalized name: SUR-FIT 45 mm Wafer, Small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mm needle with 60 U insulin diluent
Trial: 22538152
Drug: 8 mm
RxNorm normalized name: potassium 8 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mm needle with 60 U insulin diluent
Trial: 12881395
Drug: Oxaliplatin (OXA)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin (OXA) 130 mg/m² over 2 hours
Trial: 12881395
Drug: Oxaliplatin combined
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin combined with 5-fluorouracil (OXFU) 1000 mg/m²/day, continuous intravenous infusion, days 1-4
Trial: 8663944
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (100 micrograms/d in each nostril)
Trial: 8663944
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate nasal spray (100 micrograms in each nostril every 12 hours)
Trial: 1451923
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day astemizole for 3 days
Trial: 1451923
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day loratadine for 3 days
Trial: 1451923
Drug: 120 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day terfenadine forte for 3 days
Trial: 26583940
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 30% sucrose (group I, n=45)
Trial: 24412523
Drug: Trimetazidine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (35 mg orally twice a day)
Trial: 18045264
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine (PCV)
Trial: 15644067
Drug: Levodopa (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (125 mg)
Trial: 15644067
Drug: Levodopa (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (125 mg) + Selegiline (5 mg)
Trial: 10540928
Drug: Diazepam (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.7 mg/kg body weight)
Trial: 10540928
Drug: Midazolam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.3 mg/kg body weight)
Trial: 7002707
Drug: Autologous intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous intestinal contents infusion
Trial: 7002707
Drug: Artificial bile
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial bile acid solution infusion
Trial: 30489441
Drug: Self-care breath
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-care breath training program (30-min training followed by 15 min twice daily for 6 weeks)
Trial: 16676077
Drug: Antithrombin (30,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin (30,000 IU) over four days without concomitant heparin
Trial: 16676077
Drug: Antithrombin (30,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin (30,000 IU) over four days with concomitant heparin
Trial: 16676077
Drug: Antithrombin (30,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin (30,000 IU) without concomitant heparin
Trial: 16676077
Drug: Antithrombin plus
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin plus concomitant heparin
Trial: 16676077
Drug: Antithrombin with
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin with or without concomitant heparin
Trial: 11373409
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of vasopressin at 0.04 units/min for 16 hrs
Trial: 8481249
Drug: Glycopyrrolate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.2 mg intravenously)
Trial: 10852273
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 ml saline solution)
Trial: 3325934
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg enoxacin orally
Trial: 3325934
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg enoxacin orally
Trial: 3325934
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ciprofloxacin orally
Trial: 3325934
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ciprofloxacin orally
Trial: 3325934
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ciprofloxacin orally
Trial: 3325934
Drug: Ciprofloxacin 1
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1 g daily for seven days
Trial: 20547904
Drug: 9 additional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 additional months of oral valganciclovir (n = 70)
Trial: 18237364
Drug: N-of-1 trials
RxNorm normalized name: (Alginate)n+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-of-1 trials (celecoxib vs paracetamol)
Trial: 14676071
Drug: alefacept, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alefacept, 7.5 mg, in both courses (cohort 1)
Trial: 14676071
Drug: alefacept, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alefacept, 7.5 mg, in the first course and placebo in the second course (cohort 2)
Trial: 14676071
Drug: placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in the first course and alefacept, 7.5 mg, in the second course (cohort 3)
Trial: 1479656
Drug: 2 sheets
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sheets of nitroglycerin patches (5 mg each)
Trial: 1479656
Drug: 5 sheets
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 sheets of nitroglycerin patches (5 mg each)
Trial: 1479656
Drug: 10 sheets
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 sheets of nitroglycerin patches (5 mg each)
Trial: 1479656
Drug: 0 sheets
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 sheets of nitroglycerin patches (control group)
Trial: 6703268
Drug: Bupivacaine and
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine and Prilocaine (increased dose)
Trial: 30191249
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine arm (LBA) - 20 ml 1.3% bupivacaine liposomal mixed with 10 ml 0.5% bupivacaine at the sacrospinous ligament.
Trial: 30191249
Drug: Lidocaine arm
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine arm (LA) - 30 ml 0.5% lidocaine with 1:200,000 epinephrine local injection at the sacrospinous ligament.
Trial: 21586127
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative treatment
Trial: 17353373
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPD) 0.4 mg/kg administered orally 3 times per day